Home Podcasts Heart Matters
Heart Matters

Heart Matters

ReachMD 211 Episodes Aug 20, 2026

Heart Matters is a medical education podcast from ReachMD designed for cardiology physicians. It covers essential strategies and research on cardiovascular disease, including coronary artery disease, heart attacks, high cholesterol, and high blood pressure. The series aims to help clinicians improve patient heart health and stay updated on the latest cardiology research.

Episodes

Overcoming Challenges in ATTR-CM Diagnosis
Overcoming Challenges in ATTR-CM Diagnosis Aug 20, 2026 00:03:30 Guest: Sumeet Mitter MD, MSc, FACC Even with advances in noninvasive imaging, diagnosing ATTR-CM isn’t always straightforward. That's why Dr. Sumeet Mitter joins us to discuss how we can address key challenges in diagnosis and navigate the path to treatment. He's the Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inov
Multidisciplinary Care in ATTR-CM: Building the Right Team
Multidisciplinary Care in ATTR-CM: Building the Right Team Aug 20, 2026 00:03:30 Guest: Sumeet Mitter MD, MSc, FACC Because transthyretin amyloid cardiomyopathy (ATTR-CM) is a systemic disease, effective ATTR-CM management requires expertise beyond cardiology. Dr. Sumeet Mitter joins us to discuss the roles of neurology, hematology-oncology, genetic counseling, and nephrology in caring for these patients. He's the Director of Inova Schar Heart and Vascular Resear
Building Clinical Expertise in ATTR-CM Management
Building Clinical Expertise in ATTR-CM Management Aug 20, 2026 00:02:15 Guest: Sumeet Mitter MD, MSc, FACC As advances in RNA silencers, gene-editing technologies, and immunotherapy reshape the ATTR-CM landscape, it's important to stay informed and build confidence navigating this increasingly complex field. Dr. Sumeet Mitter, Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in
The Future of ATTR-CM Care: A Look at What's Next
The Future of ATTR-CM Care: A Look at What's Next Aug 20, 2026 00:04:00 Guest: Sumeet Mitter MD, MSc, FACC The future of ATTR-CM care may extend beyond slowing disease progression to detecting it sooner—and potentially reversing its effects. Dr. Sumeet Mitter, Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in Virginia, explores emerging innovations that could open the door to
Managing Acute PE: Updates from the 2026 AHA/ACC Guideline
Managing Acute PE: Updates from the 2026 AHA/ACC Guideline Aug 20, 2026 00:10:00 Host: Mary Leuchars, MD Guest: Mark Creager, MD The 2026 American College of Cardiology/American Heart Association Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults introduces a new clinical categorization framework to help evaluate risk and determine the appropriate care setting and treatment for patients with acute pulmonary embolism. Review key
From Goals to Action: Multisociety Guidance on Lipid Management
From Goals to Action: Multisociety Guidance on Lipid Management Aug 19, 2026 00:04:15 Guest: Ann Marie Navar, MD, PhD With LDL cholesterol goals reinstated in the 2026 American College of Cardiology and American Heart Association Guideline on the Management of Dyslipidemia, we now have a clearer framework for intensifying lipid-lowering therapy. Dr. Ann Marie Navar explains how to select nonstatin therapies based on the degree of LDL lowering needed, patient preferenc
Managing Dyslipidemia: 2026 ACC/AHA Guideline Updates
Managing Dyslipidemia: 2026 ACC/AHA Guideline Updates Aug 19, 2026 00:04:00 Guest: Roger Blumenthal, MD What do the 2026 American College of Cardiology (ACC) and American Heart Association (AHA) dyslipidemia guideline updates mean for patient care? Join Dr. Roger Blumenthal, Chair of the Guideline Writing Committee, as he reviews key recommendations that can help us personalize cardiovascular risk reduction and improve long-term prevention. Dr. Blumenthal is
How PCSK9 Inhibition Lowers LDL Cholesterol
How PCSK9 Inhibition Lowers LDL Cholesterol Aug 19, 2026 00:02:45 Guest: Ann Marie Navar, MD, PhD How does PCSK9 inhibition lower LDL cholesterol? Find out as Dr. Ann Marie Navar, Associate Professor of Cardiology at the University of Texas Southwestern Medical Center, explains the biology behind this therapeutic approach.
Enlicitide for LDL-C Management: Insights from CORALreef Lipids
Enlicitide for LDL-C Management: Insights from CORALreef Lipids Aug 19, 2026 00:04:30 Guest: Ann Marie Navar, MD, PhD The CORALreef Lipids trial helped establish the clinical evidence supporting the FDA approval of enlicitide for LDL-C management. Join Dr. Ann Marie Navar, Associate Professor of Cardiology at the University of Texas Southwestern Medical Center, for a discussion of the trial's efficacy, safety, and durability. She also explores key considerations for i
Risk Prediction with the PREVENT-ASCVD Equations
Risk Prediction with the PREVENT-ASCVD Equations Aug 19, 2026 00:02:45 Guest: Roger Blumenthal, MD As the drivers of cardiovascular disease have shifted over time, so have the tools used to estimate risk. Dr. Roger Blumenthal explains why the PREVENT-ASCVD equations represent an important advance over traditional models and what that means for more accurate, individualized preventive care. Dr. Blumenthal is the Kenneth Jay Pollin Professor of Cardiology
The Patient You Might Be Missing: Severe Hypertriglyceridemia in Clinical Practice
The Patient You Might Be Missing: Severe Hypertriglyceridemia in Clinical Practice Aug 14, 2026 00:16:15 Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Erin D. Michos, MD, MHS Severe hypertriglyceridemia (sHTG) affects more than 3 million people, but it often flies under the clinical radar.1-3 When triglycerides are at or above a 500 mg/dL threshold, it’s no longer just an isolated lab value—it’s a level of hypertriglyceridemia where the clinical implications change, and where a mo
Evaluating ASCVD Risk with the CPR Framework
Evaluating ASCVD Risk with the CPR Framework Aug 10, 2026 00:04:00 Guest: Roger Blumenthal, MD The 2026 American College of Cardiology (ACC) and American Heart Association (AHA) Guideline on the Management of Dyslipidemia highlights the CPR framework—Calculate, Personalize, Reclassify, and Reassess—to support individualized atherosclerotic cardiovascular disease (ASCVD) risk assessment and treatment decisions. Dr. Roger Blumenthal, Chair of the Guid

Recommended